GRP logo
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI

The citation for this report is:
Shi L, Hodges M, Drummond M, et al. Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI. Value Health 2010;13:28-33.

Translations:
» Български | » Русский

Task Force Leadership Group
Lizheng Shi PhD, MS, International Subgroup Chair & Assistant Professor, Department of  Health Systems Management, Tulane University School of Public Health and Tropical Medicine,
New Orleans, LA, USA
Michael Drummond PhD, European Subgroup Chair & Professor of Health Economics, University of York, York, UK
Meredith Hodges MPH, Student, School of Pharmacy, The University of Texas at Austin, Austin, TX, USA
Jeonghoon Ahn PhD, Assistant Professor, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
Shu Chuen Li PhD, Professor, Chair & Head, University of Newcastle, School of Biomedical Sciences, Callaghan NSW, Australia
Shanlian Li MD, Professor of Health Economics, School of Public Health, Fudan University, Shanghai, China
Federico Augustovski MD, Director, Health Economic Evaluation and Technology Assessment, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

For recommendations on how drug costs should be measured for cost-effectiveness analysis from other key analytic perspectives, please refer to the following reports:

FINAL REPORT
The Drug Cost Standards Task Force presented their reports including responses to member comments during an open forum at ISPOR’s 14th Annual International Meeting in Orlando, FL in May 2009.  The task force’s forum presentation can be viewed at: Forum Presentation


ISPOR Good Practices For Outcomes Research Index